 |
April, 6, 2005, Orlando, FL.
SurgiLight, Inc. (SRGL.OB) announced that on April
4, 2005, the Honorable G. Kendall Sharp, United States District
Judge for the Middle District of Florida, entered a final settlement
agreement between the SEC and SurgiLight, Inc. to civil litigation
stemming from the actions of J.T. Lin, founder of SurgiLight.
Dr. Lin has already received a criminal conviction for his actions.
Surgilight consented without admitting or denying the Commission's
allegations, and agreed to refrain from violating Section 10(b)
of the Securities Exchange Act of 1934 and Sections 5(a), 5(c)
and 17(a) of the Securities Act of 1933. The Commission agreed
not to assess any fees or penalties against SurgiLight or its
current officers or directors.
Dr. Colette Cozean, CEO and Chairwoman of SurgiLight, stated,
“We are glad to have this serious issue behind the Company
so that we can focus on the bright future ahead of SurgiLight.
This settlement lays to rest a chapter in our history that closed
more than three years ago when the company replaced its management
and Board of Directors and refocused the Company on its proprietary
treatment for Presbyopia.”
This media release may contain
forward-looking statements regarding but not limited to market
potential, distributor success, market size, international
approvals, FDA clearances, clinical studies and results of
those studies, marketing, future events and performance of
SurgiLight, which involve risks and uncertainties that could
materially affect actual results. Investors should refer to
documents that SurgiLight files with the SEC for a description
of certain factors that could cause actual results to vary
from current expectations and the forward-looking statements
contained in this media release.
Keywords:
surgilight, surgilight.com, SurgiLight, SurgiLight Inc.,Surgi
Light, OptiVision, presbyopia, laser presbyopia reversal,
LAPR, refractive surgery, accomodation, ophthalmology, new
trends in ophthalmology, laser, ophthalmology laster, erbium
yag, YAG, glaucoma.
|
|
|
Disclaimer:
All material herein is information supplied by the company or
other sources believed to be reliable. The information contained
herein is not guaranteed by TheNewsGate.com to be accurate,
and should not be considered to be all-inclusive. The companies
that are discussed in this profile have approved the statements
made in this profile. This profile contains forward-looking
statements that involve risks and uncertainties. Statements
in this press release about the company's future expectations,
including: development of licensing and branding and all other
statements in this release, other than historical facts, are
"forward-looking statements" within the meaning of
section 27A of the Securities Act of 1933, section 21E of the
Securities Act of 1934, as that term is defined in the Private
Securities Reform Act of 1995. It is important to note that
actual results and ultimate corporate actions could differ materially
from those in such forward looking statements. Such "forward-looking
statements" are subject to risks and uncertainties set
forth from time to time in the Company's SEC reports. This material
is for informational purposes only and should not be construed
as an offer or solicitation of an offer to buy or sell securities.
TheNewsGate.com is not a licensed broker, broker dealer, market
marker, investment advisor, analyst or underwriter. Please consult
a broker before purchasing or selling any securities viewed
on http://TheNewsGate.com/ TheNewsGate.com's affiliates, officers,
directors and employees may have bought or may buy the shares
discussed in this profile and may profit in the event those
shares rise in value. TheNewsGate.com does not and will not
offer any opinion as to when others should sell; each investor
must make that decision based on his or her judgment of the
market.
|
|
